Quoin Pharmaceuticals (QNRX) Cash & Equivalents (2017 - 2026)

Quoin Pharmaceuticals has reported Cash & Equivalents for 10 years, with the latest figure at $3.1 million in Q1 2026.

• Quarterly Cash & Equivalents fell 18.25% year-over-year to $3.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.1 million (down 18.25% YoY) and the FY2025 annual result came in at $3.8 million, up 5.37% from the prior year.
• Cash & Equivalents fell to $3.1 million in Q1 2026 per QNRX's latest filing, from $3.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $5.2 million in Q3 2022 and troughed at $1.7 million in Q2 2025.
• A 5-year average of $3.1 million and a median of $3.1 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2025: Cash & Equivalents sank 61.77% in 2022, then jumped 108.46% in 2025.
• Over 5 years, Cash & Equivalents stood at $2.9 million in 2022, then slipped by 16.06% to $2.4 million in 2023, then jumped by 50.9% to $3.6 million in 2024, then climbed by 5.37% to $3.8 million in 2025, then retreated by 18.17% to $3.1 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $3.1 million, $3.8 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.